BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 9254992)

  • 1. Comparison of oral and intravenous hydration and diuretic, choice for protecting cisplatin induced nephrotoxicity.
    Dana R; Kachhwaha VS
    Indian J Cancer; 1996 Dec; 33(4):168-70. PubMed ID: 9254992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
    Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Early phase II study of FK352 in cisplatin-induced nephropathy. Niigata Prefecture FK352 Study Group].
    Yoshizawa H; Suzuki E; Arakawa M
    Gan To Kagaku Ryoho; 1998 Nov; 25(13):2085-94. PubMed ID: 9838911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methods of reduction of cisplatin nephrotoxicity.
    Walker EM; Gale GR
    Ann Clin Lab Sci; 1981; 11(5):397-410. PubMed ID: 6277229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.
    Cornelison TL; Reed E
    Gynecol Oncol; 1993 Aug; 50(2):147-58. PubMed ID: 8375728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective evaluation of furosemide and mannitol for prevention of cisplatin-induced nephrotoxicity.
    Mach CM; Kha C; Nguyen D; Shumway J; Meaders KM; Ludwig M; Williams-Brown MY; Anderson ML
    J Clin Pharm Ther; 2017 Jun; 42(3):286-291. PubMed ID: 28276070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy.
    Morgan KP; Buie LW; Savage SW
    Ann Pharmacother; 2012 Feb; 46(2):276-81. PubMed ID: 22298599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Furosemide versus mannitol in Japanese patients with thoracic malignancy who received cisplatin-based chemotherapy using short hydration: study protocol for a randomised controlled trial.
    Murakami E; Akamatsu H; Shimokawa T; Wada K; Yamamoto N
    BMJ Open; 2019 Dec; 9(12):e029057. PubMed ID: 31831529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the rates of cisplatin (cDDP)--induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure.
    Leu L; Baribeault D
    J Oncol Pharm Pract; 2010 Sep; 16(3):167-71. PubMed ID: 19759050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A short outpatient hydration schedule for cisplatin administration.
    Al Bahrani BJ; Moylan EJ; Forouzesh B; Della-Fiorentina SA; Goldrick AJ
    Gulf J Oncolog; 2009 Jan; (5):30-6. PubMed ID: 20084783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: real or not?
    Ruggiero A; Rizzo D; Trombatore G; Maurizi P; Riccardi R
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):19-26. PubMed ID: 26589789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Administration of high doses of cisplatin in 20-minute infusions].
    Cirera L; Gay M; Tomé T; Martí M; Huguet J; Plá R
    Rev Clin Esp; 1988 Mar; 182(4):192-5. PubMed ID: 3137644
    [No Abstract]   [Full Text] [Related]  

  • 13. Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmacokinetic analysis.
    Numico G; Benasso M; Vannozzi MO; Merlano M; Rosso R; Viale M; Esposito M
    Anticancer Res; 1998; 18(2B):1313-8. PubMed ID: 9615808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trial.
    Makimoto G; Hotta K; Oze I; Ninomiya K; Nakanishi M; Hara N; Kano H; Watanabe H; Hata Y; Nishii K; Nakasuka T; Itano J; Ninomiya T; Kubo T; Ohashi K; Ichihara E; Minami D; Sato A; Tabata M; Maeda Y; Kiura K
    Asia Pac J Clin Oncol; 2021 Feb; 17(1):101-108. PubMed ID: 32885583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of preventive effects of combined furosemide and mannitol versus single diuretics, furosemide or mannitol, on cisplatin-induced nephrotoxicity.
    Takagi A; Miyoshi T; Hayashi T; Koizumi H; Tsumagari K; Yokota C; Nakano T; Matsuo K; Egawa T
    Sci Rep; 2024 May; 14(1):10511. PubMed ID: 38714773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy.
    McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF
    Support Care Cancer; 2016 Apr; 24(4):1789-93. PubMed ID: 26446698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experimental studies on the nephrotoxicity of cisplatin--amelioration of nephrotoxicity by continuous infusion].
    Izumi T
    Hinyokika Kiyo; 1988 Jan; 34(1):37-45. PubMed ID: 3132030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Protecting kidneys from radiocontrast toxicity--do fluids or drugs help?].
    Aitio ML
    Duodecim; 1999; 115(19):2075-84. PubMed ID: 11941801
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety of oral hydration after cisplatin infusion in an outpatient lung cancer unit.
    Puisset F; Bigay-Game L; Paludetto MN; Martel A; Perriat S; Rabeau A; Canonge JM; Mazieres J
    Support Care Cancer; 2019 May; 27(5):1679-1686. PubMed ID: 30120556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research.
    Ali BH; Al Moundhri MS
    Food Chem Toxicol; 2006 Aug; 44(8):1173-83. PubMed ID: 16530908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.